{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:20:54Z","timestamp":1788009654662,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13555-024-01292-z","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:01:16Z","timestamp":1731085276000},"page":"3273-3290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04102007","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bukhalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Drogaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Stakias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rubant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"1292_CR1","unstructured":"Organization WH. 2016 Global report on psoriasis [Internet]. [cited 2023 Feb 13]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf.psoriasis?sequence=1"},{"key":"1292_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","volume":"14","author":"W-H Boehncke","year":"2013","unstructured":"Boehncke W-H, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14:377\u201388.","journal-title":"Am J Clin Dermatol"},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/PTT.S328447","volume":"12","author":"B Blackstone","year":"2022","unstructured":"Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis Targets Ther. 2022;12:25\u201333.","journal-title":"Psoriasis Targets Ther"},{"key":"1292_CR4","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/jdv.17348","volume":"35","author":"CC von St\u00fclpnagel","year":"2021","unstructured":"von St\u00fclpnagel CC, Augustin M, D\u00fcpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases\u2014a systematic review. J Eur Acad Dermatol Venereol. 2021;35:2166\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1292_CR5","first-page":"553","volume":"32","author":"V Bulat","year":"2020","unstructured":"Bulat V, \u0160itum M, A\u017edaji\u0107 MD, Lovri\u0107 I, Dediol I. Study on the impact of psoriasis on quality of life: psychological. Soc Financ Implic Psychiatr Danub. 2020;32:553\u201361.","journal-title":"Soc Financ Implic Psychiatr Danub"},{"key":"1292_CR6","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam phys Med Fam Can. 2017;63:278\u201385.","journal-title":"Can Fam phys Med Fam Can"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37:35\u201355.","journal-title":"BioDrugs"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.19325","volume":"183","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183:638\u201349.","journal-title":"Br J Dermatol"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/BTT.S252578","volume":"15","author":"ND Brownstone","year":"2021","unstructured":"Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, et al. Biologic treatments of psoriasis: an update for the clinician. Biol Targets Ther. 2021;15:39\u201351.","journal-title":"Biol Targets Ther"},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","volume":"9","author":"BE Strober","year":"2019","unstructured":"Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9:5\u201318.","journal-title":"Dermatol Ther"},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatol Treat. 2023;34:2200870.","journal-title":"J Dermatol Treat"},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778\u201391.","journal-title":"MAbs"},{"key":"1292_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","journal-title":"J Exp Med"},{"issue":"5","key":"1292_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","volume":"189","author":"LFS Gold","year":"2023","unstructured":"Gold LFS, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023;189(5):540\u201352.","journal-title":"Br J Dermatol"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650\u201361.","journal-title":"Lancet"},{"key":"1292_CR16","doi-asserted-by":"publisher","first-page":"AD88","DOI":"10.1016\/j.jaad.2021.06.375","volume":"85","author":"TF Cestari","year":"2021","unstructured":"Cestari TF, daSilva Souza C, Azulay-Abulafia L, Fabricio L, Kalabic J. 26197 Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil. J Am Acad Dermatol. 2021;85:AD88.","journal-title":"J Am Acad Dermatol"},{"key":"1292_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjd.20481","volume":"186","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, et al. Direct comparison of risankizumab and fumaric acid esters in systemic therapy\u2013na\u00efve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial*. Br J Dermatol. 2022;186:30\u20139.","journal-title":"Br J Dermatol"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy\u2013assessor-blinded clinical trial*. Br J Dermatol. 2021;184:50\u20139.","journal-title":"Br J Dermatol"},{"key":"1292_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394:576\u201386.","journal-title":"Lancet"},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1080\/09546634.2022.2095328","volume":"33","author":"B Strober","year":"2022","unstructured":"Strober B, Armstrong A, Rubant S, Patel M, Wu T, Photowala H, et al. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. J Dermatol Treat. 2022;33:2991\u20136.","journal-title":"J Dermatol Treat"},{"key":"1292_CR21","unstructured":"Services US Department of Health and Human. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 2018; Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605\u201313.","journal-title":"J Immunol"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9:111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"key":"1292_CR24","doi-asserted-by":"publisher","first-page":"17675","DOI":"10.1038\/s41598-019-53240-z","volume":"9","author":"AK Kannan","year":"2019","unstructured":"Kannan AK, Su Z, Gauvin DM, Paulsboe SE, Duggan R, Lasko LM, et al. IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases. Sci Rep. 2019;9:17675.","journal-title":"Sci Rep"},{"key":"1292_CR25","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2011.200","volume":"131","author":"DC Soler","year":"2011","unstructured":"Soler DC, McCormick TS. The dark side of regulatory T cells in psoriasis. J Investig Dermatol. 2011;131:1785\u20136.","journal-title":"J Investig Dermatol"},{"key":"1292_CR26","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, Nyl\u00e9n S, Talme T, St\u00e5hle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192:3111\u201320.","journal-title":"J Immunol"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"269rvl","DOI":"10.1126\/scitranslmed.3010641","volume":"7","author":"RA Clark","year":"2015","unstructured":"Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7:269rvl.","journal-title":"Sci Transl Med"},{"key":"1292_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich K, Weisenseel P, Pinter A, Sch\u00e4kel K, Asadullah K, Wegner S, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11: e049822.","journal-title":"BMJ Open"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni.2416","volume":"13","author":"Y Lee","year":"2012","unstructured":"Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012;13:991\u20139.","journal-title":"Nat Immunol"},{"key":"1292_CR30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh Y-CM, Maari C, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with Guselkumab vs Secukinumab. J Investig Dermatol. 2021;141:1707\u201317189.","journal-title":"J Investig Dermatol"},{"key":"1292_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","volume":"10","author":"MJ McGeachy","year":"2009","unstructured":"McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17\u2013producing effector T helper cells in vivo. Nat Immunol. 2009;10:314\u201324.","journal-title":"Nat Immunol"},{"key":"1292_CR32","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","volume":"40","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023;40:3410\u201333.","journal-title":"Adv Ther"},{"key":"1292_CR33","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","volume":"14","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Blauvelt A, Bachelez H, Coates LC, den Bosch FEV, Kaplan B, et al. Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials. Dermatol Ther. 2024;14:2523\u201338.","journal-title":"Dermatol Ther"},{"key":"1292_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"1292_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28:390\u2013403.","journal-title":"Dermatol Ther"},{"key":"1292_CR36","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/j.1468-3083.2010.03944.x","volume":"25","author":"J-P Ortonne","year":"2011","unstructured":"Ortonne J-P, Chimenti S, Reich K, Gniadecki R, Spr\u00f8gel P, Unnebrink K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol. 2011;25:1012\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1292_CR37","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1038\/s41598-022-18790-9","volume":"12","author":"T Graier","year":"2022","unstructured":"Graier T, Weger W, Jonak C, Sator P, Zikeli C, Prillinger K, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12:15078.","journal-title":"Sci Rep"},{"key":"1292_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14144","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12\/23 and\/or anti IL-23: preliminary data of a real-life 16-week retrospective study. Dermatol Ther. 2020;33: e14144.","journal-title":"Dermatol Ther"},{"key":"1292_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14584","volume":"34","author":"C Bonifati","year":"2021","unstructured":"Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. a real-life experience. Dermatol Ther. 2021;34: e14584.","journal-title":"Dermatol Ther"},{"key":"1292_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13555-023-01064-1","volume":"14","author":"Y Tada","year":"2024","unstructured":"Tada Y, Soliman AM, Ishii K, Sakuma R, Puig L, Davis M, et al. Real-world discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan. Dermatol Ther. 2024;14:99\u2013114.","journal-title":"Dermatol Ther"},{"key":"1292_CR41","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628\u201337.","journal-title":"Br J Dermatol"},{"key":"1292_CR42","unstructured":"Cristina; E, Kogan, Nora. Argentine Guidelines for the systemic treatment of moderate-to-severe psoriasis. [Internet]. [cited 2023 Sep 19]. Available from: https:\/\/www.soarpso.org\/recursos\/archivos\/AG_psoriasis_2020_english.pdf"},{"key":"1292_CR43","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, Valle GA, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1292_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, Valle GA, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35:281\u2013317.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1292_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"JM Carrascosa","year":"2022","unstructured":"Carrascosa JM, Puig L, Romero IB, Salgado-Boquete L, del Alc\u00e1zar E, Lencina JJA, et al. Actualizaci\u00f3n pr\u00e1ctica de las recomendaciones del Grupo de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (GPS) para el tratamiento de la psoriasis con terapia biol\u00f3gica. Parte 2 \u00abManejo de poblaciones especiales, pacientes con comorbilidad y gesti\u00f3n del riesgo. Actas Dermo-Sifiliogr. 2022;113:583\u2013609.","journal-title":"Actas Dermo-Sifiliogr"},{"key":"1292_CR46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"JM Carrascosa","year":"2022","unstructured":"Carrascosa JM, Puig L, Romero IB, Salgado-Boquete L, del Alc\u00e1zar E, Lencina JJA, et al. [Translated article] practical update of the recommendations published by the psoriasis group of the spanish academy of dermatology and venereology (GPs) on the treatment of psoriasis with biologic therapy. part 1. concepts and general management of psoriasis with biologic therapy. Actas Dermo-Sifiliogr. 2022;113:261\u201377.","journal-title":"Actas Dermo-Sifiliogr"},{"key":"1292_CR47","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1080\/09546634.2022.2114783","volume":"33","author":"A Sevagamoorthy","year":"2022","unstructured":"Sevagamoorthy A, Sockler P, Akoh C, Takeshita J. Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. J Dermatol Treat. 2022;33:3086\u201397.","journal-title":"J Dermatol Treat"},{"key":"1292_CR48","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjd.19468","volume":"184","author":"VD Reddy","year":"2021","unstructured":"Reddy VD, Myers BA, Chan SY, Thibodeaux QG, Brownstone ND, Bhutani T, et al. A review of current phase III clinical trials of plaque psoriasis: under-representation of nonwhite participants and need for reform. Br J Dermatol. 2021;184:348\u201350.","journal-title":"Br J Dermatol"}],"updated-by":[{"DOI":"10.1007\/s13555-024-01328-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01292-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01292-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01292-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:12:37Z","timestamp":1737097957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01292-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01292-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-024-01328-4","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-024-01328-4","URL":"https:\/\/doi.org\/10.1007\/s13555-024-01328-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Richard B. Warren has received grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Novartis, and Pfizer. He has received personal fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, Lilly, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Lev Pavlovsky has served as an investigator for AbbVie, Coherus, Novartis Pharmaceuticals Corporation, Janssen Biotech, Eli Lilly, Bristol Myers Squibb and as an adviser, consultant, and\/or invited lecturer for AbbVie, Janssen Biotech, Novartis Pharmaceuticals Corporation, Pfizer Inc., Dexcel Pharma, Eli Lilly, and Boehringer Ingelheim. Antonio Costanzo has served as a clinical study investigator for AbbVie, has received research grants and\/or speaker\/ad board honoraria from AbbVie, Eli Lilly, Amgen, Almirall, Leo Pharma, Novartis, UCB, and Pfizer, and is currently affiliated with ESDR (member), Sidemast (member), and EDF (board member). Michael Bukhalo has received honoraria or fees for serving on advisory boards, as a speaker, as a consultant, and grants as an investigator from Allergan, Boehringer Ingelheim, Celgene, Centocor, DUSA Pharmaceuticals, Eli Lilly, Galderma, Leo Pharma, MedImmune, Merck, and Novartis. Neil J. Korman has served as an investigator, speaker, adviser, or consultant for AbbVie, Abcentra, Amgen, Argenx, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celgene, Chemocentryx, Dermavant, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin Pharma, Leo Pharma, Menlo Therapeutics, Novartis, OliX Pharma, Pfizer, Prothena, Principia, Regeneron, Rhizen, Sanofi, Soligenix, Sun Pharma, Syntimmune, Trevi, UCB, and XBiotech. Yu-Huei Huang has conducted clinical trials while serving as a principal investigator for Galderma, Eli Lilly, Novartis Pharmaceuticals Corporation, and Janssen-Cilag Pharmaceutica; received honoraria for serving as an advisory board member for Pfizer Limited, AbbVie, and Celgene; and received speaking fees from AbbVie, Eli Lilly, and Novartis Pharmaceuticals Corporation. Georgios Kokolakis has received travel grants or honoraria, has been a consultant member of advisory boards and speaker bureaus, or has served as an investigator for AbbVie, Actelion, Almirall, Amgen, Basilea, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Hexal-Sandoz, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Sanofi-Aventis, Stada, Takeda and UCB. Andreas Pinter is an investigator and\/or speaker and\/or adviser for the following pharmaceutical companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, GSK, Eli Lilly, Galderma, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough, UCB Pharma and Zuellig Pharma. Simone Rubant, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Ahmed M. Soliman, and Vassilis Stakias are full-time employees of AbbVie and may own stock\/options or patents. Diamant Tha\u00e7i is an adviser, speaker, and\/or consultant for AbbVie, Almirall, Amgen, Asana Biosciences, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen, Kyowa Kirin, LEO Pharma, Lilly, New Bridge, Novartis, Pfizer, Regeneron, Sanofi\/Genzyme, Tamro, UCB, and Zuellig Pharma. He is also involved in research for AbbVie, LEO Pharma, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approvals were obtained from local ethics committees, and the patients provided written informed consent. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}